| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.074 | 0.05 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.05 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.073 | 0.05 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.077 | 0.05 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.05 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.073 | 0.05 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.077 | 0.05 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.079 | 0.05 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.31 | 0.06 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.077 | 0.06 |